Sequential methotrexate and 5-fluorouracil in the primary treatment of metastatic colorectal carcinoma

J. A. Ajani, M. D. Kanojia, A. Y. Bedikian, J. K. Korinek, S. H. Stein, E. G. Espinoza, G. P. Bodey

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Thirty-three patients with metastatic colorectal carcinoma were treated with sequential conventional dose methotrexate (60 mg/m2) followed within 1 hour by 5-fluorouracil (1000 mg/m2) every 3 weeks. Thirty of 33 patients were assessable for response. One patient (3%) achieved a partial remission (3.5 months). Three patients demonstrated minor tumor regressions. In an additional 17 patients, tumor stabilization was observed. The treatments were tolerated without any significant morbidity. A disappointingly low response rate was observed in our study as opposed to previous reports. Further clinical studies are necessary to establish the optimum dose levels and scheduling of sequential methotrexate and 5-fluorouracil.

Original languageEnglish (US)
Pages (from-to)69-71
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume8
Issue number1
DOIs
StatePublished - 1985

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Sequential methotrexate and 5-fluorouracil in the primary treatment of metastatic colorectal carcinoma'. Together they form a unique fingerprint.

Cite this